RegulatoryCompany release

Neurogene Counts All 25 Patients in Rett Gene Therapy Pivotal Analysis; Data Due 2H 2027

🇺🇸 Neurogene Inc. (NGNE) · Mon 09 Nov 2026

Neurogene says the primary analysis of its NGN-401 Embolden trial will include every dosed participant, with topline results expected in the second half of 2027 and PPQ runs due by year-end.

Neurogene reported third-quarter results on 9 November 2026, alongside an update on NGN-401, its investigational AAV9 gene therapy for Rett syndrome. The company said topline data from the Embolden registrational trial are expected in the second half of 2027.

A key change concerns the trial's primary analysis, which will now count all 25 dosed participants. Neurogene said this change was aligned with the US Food and Drug Administration through the agency's START Pilot Program. The success threshold is set at 9 of 25 responders.

On manufacturing, the company said process performance qualification (PPQ) runs supporting the planned biologics licence application (BLA) are on track for completion by the end of 2026. PPQ is the stage at which a manufacturer demonstrates that its commercial-scale process consistently delivers product of the intended quality.

On safety, Neurogene said the 1E15 vg dose of NGN-401 remains generally well tolerated, based on data from 35 patients. The company also reported cash of $359.7 million, which it said is sufficient to fund operations into the first quarter of 2029.

What it means for your team

  • The fixed responder threshold (9 of 25) and inclusion of all dosed participants give a clear benchmark for how the pivotal result will be judged.
  • Completion of PPQ runs by end-2026 is a key CMC milestone ahead of any BLA submission; quality teams should watch for confirmation.
  • The safety dataset (N=35 at 1E15 vg, generally well tolerated) will be central to the benefit-risk discussion and to any future pharmacovigilance planning for an AAV9 therapy.
  • Cash runway into Q1 2029 suggests funding is in place beyond the expected topline readout, relevant for assessing programme continuity.

Company's press release (SEC filing): Neurogene Inc. ↗

Article written by VigiEye from the official source (Neurogene Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →